Sotabase

Career

· Director, School Of Data Science, Old Dominion University2023–
· Full Professor, Old Dominion University2023–
· Research Manager (Group Leader), Oak Ridge National Laboratory2020–2023
· Distinguished Scientist, Oak Ridge National Laboratory2019–2023
· Adjunct Professor, Texas A&M University2017–
· Research Staff Member, IBM2001–2019
· Ph.D., Electrical and Computer Engineering, Carnegie Mellon University
· M.S, Applied Mathematics and Statistics, University of Minnesota-Duluth

Publications (90)

A Global Overview of the Impact of Peritoneal Dialysis First or Favored Policies: An Opinion
Peritoneal Dialysis International · 2015
138
cited
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
PharmacoEconomics (Auckland) · 2017
121
cited
A global overview of renal registries: a systematic review
BMC Nephrology · 2015
100
cited
Bloodstream infections associated with parenteral nutrition preparation methods in the United States: a retrospective, large database analysis.
JPEN - Journal of Parenteral and Enteral Nutrition · 2012
71
cited
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
Journal of Managed Care & Specialty Pharmacy · 2017
66
cited
Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis from a UK Payer Perspective
Applied Health Economics and Health Policy · 2014
63
cited
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
PLoS ONE · 2018
59
cited
Economic Evaluation of Urgent-Start Peritoneal Dialysis Versus Urgent-Start Hemodialysis in the United States
Medicine · 2014
57
cited
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
Journal of Medical Economics · 2017
56
cited
Nutrition therapy cost analysis in the US
Applied Health Economics and Health Policy · 2011
56
cited
The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility.
Health Services Research · 2011
54
cited
Herbal Medicine Regulation in China, Germany, and the United States
2010
44
cited
Is there a difference in bloodstream infections in critically ill patients associated with ready-to-use versus compounded parenteral nutrition?
Clinical Nutrition · 2012
40
cited
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
Journal of immunotherapy · 2017
30
cited
Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Future Oncology · 2021
29
cited
Financial Implications to Medicare from Changing the Dialysis Modality Mix under the Bundled Prospective Payment System
Peritoneal Dialysis International · 2014
28
cited
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
Patient Preference and Adherence · 2017
28
cited
Real-world treatment patterns and clinical outcomes among patients with advanced melanoma
Medicine · 2019
27
cited
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Journal of Medical Economics · 2019
26
cited
The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors
The Oncologist · 2021
25
cited
Sotabase